CD66a/CEACAM1
Alpha Lifetech can provide CD66a/CEACAM1 corresponding products, help each customer's research and development.
01
Introduction To CD66a/CEACAM1
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD66a/CEACAM1 protein is a common target in medicine.
CD66a, also known as bile glycoprotein (BGP), is a carcinoembryonic antigen (CEA) family member and the immunoglobulin superfamily. CD66a (CEACAM1) is an adhesion molecule with regulatory functions on T lymphocytes, CD66a is a human homolog of Cell-CAM, and Cell-CAM is a well-defined cell adhesion molecule in the rat. CD66a (CEACAM1) was found to be expressed in epithelial, certain endothelial, and myeloid cells, and on a few mouse natural killer (NK) cells, especially in the liver. CD66a expression on NK cells depends on its stage of differentiation, with the highest expression levels on immature NK cells.
Function of Target CD66a/CEACAM1
CD66a Is a member of the carcinoembryonic antigen family and is thought to function as intercellular adhesion molecules and cell growth regulators. CD66a homologous (65% identical) has been shown to have tumor suppressor activity. This homology suggests that CD66a may also function as a tumor suppressor. Loss of CD66a protein plays an important role in the development of prostate cancer, and restoring CD66a expression may provide effective therapies for prostate cancer. CD66a can regulate cell signaling, proliferation, and tumor growth. Some scientists have found that CEACAM1 affects the resolution of inflammation by prolonging the survival time of rat granulocytes. Meanwhile, CD66a amplified T cell activation and thus could promote crosstalk between epithelial cells and T lymphocytes in the intestinal immune response.
Gene Pathway of Target CD66a/CEACAM1
Studies have shown a link between CEACAM1 and apoptosis, including a recent demonstration that ERK 1 / 2 signaling is triggered downstream of CEACAM1. CEACAM1-binding triggers phosphatidylinositol 3-kinase-dependent activation of the protein kinase Akt without affecting the activity of the extracellular signal-related kinase ERK, while the phosphatidylinositol 3-kinase-specific inhibitor LY294002 effectively blocks the protective effect of CEACAM1. CEACAM1 Ensign phosphatidylinositol 3-kinase and Akt-dependent survival signals and suppresses mitochondria-dependent apoptosis in monocytes. Meanwhile, by controlling the ERK / MEK and PI3K / Akt pathways, CEACAM1 functions as a key regulator of the contact-dependent control of cell survival, differentiation, and growth. The binding of CEACAM1-specific antibodies, Fab fragments, and soluble CEACAM1-Fc constructs to CEACAM1 expression on the cell surface resulted in spontaneous and Fas ligand (CD95L) -induced delayed apoptosis. Tyrosine phosphorylation of CEACAM1-L, its binding to SHP-1, and activation of Erk 1 / 2 and caspase-3 appear to be critical for the CEACAM1-mediated anti-apoptotic effects.
Fig 1: CDEACAM1 Gene Pathway. (Reference source: Götz L, Rueckschloss U, Balk G, Pfeiffer V, Ergün S, Kleefeldt F. The role of carcinoembryonic antigen-related cell adhesion molecule 1 in cancer. Front Immunol. 2023 Nov 24;14:1295232.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD66a/CEACAM1 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD66a/CEACAM1 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD66a/CEACAM1 protein products are also essential. Alpha Lifetech can provide CD66a/CEACAM1 corresponding products and help each customer's research and development. Alpha Lifetech provides end-to-end biotechnology development solutions, from upstream cell culture optimization to downstream purification scale. Our process is validated through analytical techniques such as HPLC, SDS-PAGE, and mass spectrometry to ensure product consistency and regulatory compliance. By combining cutting-edge biotechnology expertise with flexible service models, we help clients accelerate project research progress and ensure smooth experimentation.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64665 | 50ug,100ug,500ug | |
| ADT1026 | ADT1026-Altumomab Biosimilar-Anti CEACAM5/CD66e mAb- Research Grade |
1mg,5mg |
| ADT1675 | ADT1675-Tusamitamab Biosimilar-Anti CEACAM5/CEA/CD66e mAb- Research Grade |
100ug,1mg,5mg |
| ADT1051 | ADT1051-Arcitumomab Biosimilar-Anti CEACAM5/CD66e mAb- Research Grade |
1mg,5mg |
| ADT1154 | ADT1154-cT84.66 Biosimilar-Anti CEACAM5/CD66e mAb- Research Grade |
1mg,5mg |
| ADT1127 | ADT1127-Cergutuzumab Amunaleukin Biosimilar-Anti CEACAM5/CD66e mAb- Research Grade |
1mg,5mg |
| ADT1334 | ADT1334-Labetuzumab Biosimilar-Anti CEACAM5 mAb- Research Grade |
100ug,1mg,5mg |
| ADT1655 | ADT1655-Tinurilimab Biosimilar-Anti CEACAM6 mAb- Research Grade |
100ug,1mg,5mg |
| ADT1089 | ADT1089-Besilesomab Biosimilar-Anti CEACAM8/CD66b mAb- Research Grade |
1mg,5mg |
Reference
[1] Thirion G, Feliu AA, Coutelier JP. CD66a (CEACAM1) expression by mouse natural killer cells. Immunology. 2008 Dec;125(4):535-40.
[2] Satoh Y, Hayashi T, Takahashi T, Itoh F, Adachi M, Fukui M, Kuroki M, Kuroki M, Imai K, Hinoda Y. Expression of CD66a in multiple myeloma. J Clin Lab Anal. 2002;16(2):79-85.
[3] Prall F, Nollau P, Neumaier M, Haubeck HD, Drzeniek Z, Helmchen U, Löning T, Wagener C. CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. J Histochem Cytochem. 1996 Jan;44(1):35-41.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102